My personal journey with cancer has been a long and painful one. I lost my sister to triple-negative breast cancer, and currently, my mother is battling the same disease with metastases to her liver, lungs, and bones. As a survivor of lobular breast cancer myself and an active patient advocate, I am all too familiar with the importance of having access to effective treatments.

Trodelvy (Sacituzumab Govitecan) is a drug that has shown significant promise in treating patients with metastatic triple-negative breast cancer. In clinical trials conducted by Gilead Sciences Inc., Trodelvy demonstrated substantial improvements in overall survival rates compared to standard chemotherapy (Source: FDA). Despite these promising results, this potentially life-saving drug is not yet approved in Denmark due to its high cost.

This leaves Denmark as the ONLY country in Scandinavia and one of the few countries in Europe to NOT have approved this critical treatment.  

The Danish Medicines Agency must recognize the urgency of this situation. Every day without access to effective treatment options like Trodelvy can mean a difference between life and death for those suffering from advanced stages of triple-negative breast cancer.

We urge the Danish authorities to expedite the approval process for Trodelvy so that patients like my mother have a fighting chance against this aggressive form of cancer, that is already notoriously difficult to treat.

Please sign this petition if you believe that every individual deserves access to potentially life-saving treatments when they need them most.

#dyingforacure #stage4needsmore #alloutofribbons #bcsm #tnbc #mtnbc